Your browser is no longer supported. Please, upgrade your browser.
LUNG [NASD]
Pulmonx Corporation
Index- P/E- EPS (ttm)-1.24 Insider Own4.00% Shs Outstand36.45M Perf Week-17.49%
Market Cap907.30M Forward P/E- EPS next Y-1.24 Insider Trans-12.45% Shs Float33.81M Perf Month-25.86%
Income-45.00M PEG- EPS next Q-0.36 Inst Own98.60% Short Float4.72% Perf Quarter-39.92%
Sales44.50M P/S20.39 EPS this Y-48.00% Inst Trans5.50% Short Ratio4.17 Perf Half Y-40.75%
Book/sh5.56 P/B4.28 EPS next Y8.90% ROA-18.80% Target Price49.33 Perf Year-63.83%
Cash/sh5.25 P/C4.54 EPS next 5Y37.70% ROE-22.30% 52W Range24.45 - 68.76 Perf YTD-25.72%
Dividend- P/FCF- EPS past 5Y- ROI-13.40% 52W High-65.36% Beta-
Dividend %- Quick Ratio9.60 Sales past 5Y- Gross Margin72.90% 52W Low-2.58% ATR1.94
Employees170 Current Ratio10.20 Sales Q/Q25.50% Oper. Margin- RSI (14)26.25 Volatility7.27% 6.41%
OptionableYes Debt/Eq0.09 EPS Q/Q-158.10% Profit Margin- Rel Volume1.21 Prev Close24.63
ShortableYes LT Debt/Eq0.07 EarningsNov 02 AMC Payout- Avg Volume382.89K Price23.82
Recom1.80 SMA20-22.72% SMA50-27.94% SMA200-38.92% Volume462,707 Change-3.29%
Dec-08-21Upgrade Piper Sandler Neutral → Overweight $45
Apr-01-21Initiated Citigroup Buy $60
Mar-25-21Initiated Piper Sandler Neutral $50
Mar-10-21Upgrade BofA Securities Neutral → Buy $72
Jan-04-21Downgrade BofA Securities Buy → Neutral
Oct-26-20Initiated Wells Fargo Equal Weight $46
Oct-26-20Initiated Stifel Buy $50
Oct-26-20Initiated Morgan Stanley Equal-Weight $44
Oct-26-20Initiated Canaccord Genuity Buy $49
Oct-26-20Initiated BofA Securities Buy $50
Jan-17-22 06:36AM  
Jan-12-22 02:58PM  
Jan-04-22 10:00AM  
Dec-29-21 04:05PM  
Dec-24-21 12:38AM  
Dec-18-21 09:15AM  
12:38AM  
Dec-08-21 07:21AM  
Nov-17-21 11:58AM  
Nov-16-21 04:05PM  
Nov-03-21 08:00AM  
04:01AM  
Nov-02-21 06:45PM  
04:05PM  
07:52AM  
Oct-27-21 12:35PM  
Oct-26-21 04:05PM  
Oct-20-21 09:08AM  
Sep-21-21 04:05PM  
10:44AM  
Sep-07-21 05:00PM  
Aug-26-21 04:05PM  
Aug-20-21 04:30PM  
Aug-04-21 09:01AM  
Aug-03-21 04:05PM  
Aug-02-21 08:45AM  
Jul-29-21 04:05PM  
Jul-27-21 09:14AM  
Jul-20-21 06:45PM  
04:05PM  
Jul-19-21 04:28AM  
Jul-13-21 01:41PM  
May-17-21 04:05PM  
May-07-21 01:51AM  
May-05-21 04:31AM  
May-04-21 04:02PM  
04:01PM  
02:30PM  
Apr-27-21 04:05PM  
Apr-20-21 04:05PM  
Mar-10-21 10:03AM  
Mar-04-21 01:30AM  
Mar-02-21 10:00PM  
04:01PM  
02:30PM  
Feb-16-21 04:01PM  
Jan-28-21 09:02AM  
Jan-01-21 12:54AM  
Dec-08-20 08:13AM  
Nov-30-20 08:00AM  
Nov-10-20 04:01PM  
02:45PM  
Nov-03-20 08:00AM  
Nov-02-20 10:00AM  
Oct-22-20 04:01PM  
Oct-05-20 04:01PM  
Oct-02-20 11:23AM  
Oct-01-20 12:09PM  
11:57AM  
11:36AM  
Sep-30-20 10:36PM  
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
French Glendon E. IIIPresident and CEODec 16Sale31.0525,000776,2201,113,949Dec 17 08:06 PM
Rose Geoffrey BeranChief Commercial OfficerDec 15Sale30.5522,000672,002123,459Dec 16 06:22 PM
Sung DerrickChief Financial OfficerDec 15Sale30.533,00091,585225,420Dec 16 05:48 PM
Sung DerrickChief Financial OfficerDec 14Sale32.893,00098,670228,420Dec 16 05:48 PM
French Glendon E. IIIPresident and CEODec 01Sale32.731,42146,5091,138,949Dec 03 07:11 PM
Lehman David AaronGeneral CounselDec 01Sale32.7338312,53616,834Dec 03 06:41 PM
Rose Geoffrey BeranChief Commercial OfficerDec 01Sale32.7335511,619145,459Dec 03 06:39 PM
Sung DerrickChief Financial OfficerDec 01Sale32.7338312,536231,420Dec 03 06:34 PM
French Glendon E. IIIPresident and CEONov 18Sale35.9825,000899,4711,105,370Nov 22 06:44 PM
Rose Geoffrey BeranChief Commercial OfficerNov 15Sale39.947,000279,580145,814Nov 16 06:09 PM
French Glendon E. IIIPresident and CEOOct 21Sale39.7525,000993,6811,130,370Oct 22 07:11 PM
Rose Geoffrey BeranChief Commercial OfficerOct 15Sale39.447,000276,080152,814Oct 18 08:09 PM
Sung DerrickChief Financial OfficerSep 21Sale37.503,000112,500231,803Sep 21 08:11 PM
Sung DerrickChief Financial OfficerSep 20Sale37.353,000112,062234,803Sep 21 08:11 PM
French Glendon E. IIIPresident and CEOSep 20Sale37.3623,571880,6240Sep 20 08:45 PM
French Glendon E. IIIPresident and CEOSep 16Sale38.8625,000971,5001,155,370Sep 20 08:45 PM
Rose Geoffrey BeranChief Commercial OfficerSep 15Sale38.127,000266,840159,814Sep 17 06:42 PM
Sung DerrickChief Financial OfficerSep 01Sale40.0938315,354237,803Sep 03 05:58 PM
Rose Geoffrey BeranChief Commercial OfficerSep 01Sale40.0935514,232166,814Sep 03 05:55 PM
Lehman David AaronGeneral CounselSep 01Sale40.0938315,35417,217Sep 03 05:53 PM
French Glendon E. IIIPresident and CEOSep 01Sale40.091,42156,9681,180,370Sep 03 05:50 PM
French Glendon E. IIIPresident and CEOAug 19Sale36.591,00036,59023,571Aug 23 06:31 PM
French Glendon E. IIIPresident and CEOAug 19Sale36.6325,000915,7501,181,791Aug 23 06:31 PM
Rose Geoffrey BeranChief Commercial OfficerAug 16Sale36.717,000256,970166,885Aug 18 08:09 PM
French Glendon E. IIIPresident and CEOJul 15Option Exercise2.204,3759,6251,231,734Jul 19 07:48 PM
Rose Geoffrey BeranChief Commercial OfficerJul 15Sale38.737,000271,080173,885Jul 19 07:49 PM
French Glendon E. IIIPresident and CEOJul 15Sale38.701,00038,70324,571Jul 19 07:48 PM
French Glendon E. IIIPresident and CEOJul 15Sale38.7325,000968,2041,206,734Jul 19 07:48 PM
BOSTON SCIENTIFIC CORP10% OwnerJul 13Sale37.452,500,00093,625,0001,488,106Jul 14 04:10 PM
Florin Daniel PDirectorJul 12Buy40.002,500100,0007,532Jul 13 07:21 PM
Florin Daniel PDirectorJun 25Buy44.122,22298,0355,032Jun 28 05:33 PM
French Glendon E. IIIPresident and CEOJun 17Option Exercise2.204,3759,6251,252,359Jun 21 06:26 PM
French Glendon E. IIIPresident and CEOJun 17Sale42.681,00042,68025,571Jun 21 06:26 PM
French Glendon E. IIIPresident and CEOJun 17Sale42.9625,0001,073,9051,227,359Jun 21 06:26 PM
Rose Geoffrey BeranChief Commercial OfficerMay 24Sale40.884,797196,085163,285May 25 05:18 PM
French Glendon E. IIIPresident and CEOMay 20Sale40.751,00040,75026,571May 21 05:25 PM
French Glendon E. IIIPresident and CEOMay 20Sale41.9525,0001,048,7801,199,884May 21 05:25 PM
Rose Geoffrey BeranChief Commercial OfficerMay 18Option Exercise1.4049,42869,199166,101May 19 05:19 PM
Rose Geoffrey BeranChief Commercial OfficerMay 10Sale40.704,797195,247116,673May 11 06:58 PM
Rose Geoffrey BeranChief Commercial OfficerApr 19Sale43.244,797207,422121,470Apr 21 05:26 PM
French Glendon E. IIIPresident and CEOApr 15Sale43.701,00043,70027,571Apr 16 05:03 PM
French Glendon E. IIIPresident and CEOApr 15Sale43.7525,0001,093,8561,224,884Apr 16 05:03 PM
BOSTON SCIENTIFIC CORP10% OwnerApr 06Sale43.60650,00028,340,0003,988,106Apr 08 04:20 PM
Sung DerrickChief Financial OfficerApr 06Sale47.125,000235,602218,659Apr 06 07:40 PM
Rose Geoffrey BeranChief Commercial OfficerApr 05Sale47.644,797228,521109,064Apr 06 07:41 PM
Sung DerrickChief Financial OfficerApr 05Sale47.605,000238,020223,659Apr 06 07:40 PM